Bausch Health Companies Inc. Research and Development Asset Acquired Other than Through Business Combination, Written-off
Bausch Health Companies Inc. (BHC) reported Research and Development Asset Acquired Other than Through Business Combination, Written-off of $109.20 million for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-29.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff · last filed 2012-02-29
- Bausch Health Companies Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2011-12-31 was $105.20M, a 275.71% increase year-over-year.
- Bausch Health Companies Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2011-09-30 was $0.00.
- Bausch Health Companies Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2011-06-30 was $2.00M, a 80.47% decline year-over-year.
- Bausch Health Companies Inc. research and development asset acquired other than through business combination, written-off for the quarter ending 2011-03-31 was $2.00M, a 96.08% decline year-over-year.
- Bausch Health Companies Inc. research and development asset acquired other than through business combination, written-off for fiscal 2011 was $109.20M, a 22.36% increase from fiscal 2010.
- Bausch Health Companies Inc. research and development asset acquired other than through business combination, written-off for fiscal 2010 was $89.25M, a 50.36% increase from fiscal 2009.
- Bausch Health Companies Inc. research and development asset acquired other than through business combination, written-off for fiscal 2009 was $59.35M.
| Period end | Research and Development Asset Acquired Other than Through Business Combination, Written-off 3 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 6 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 9 month | Research and Development Asset Acquired Other than Through Business Combination, Written-off 12 month |
|---|---|---|---|---|
| 2011-12-31 | $105.20M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $105.20M derived: sum of 2 quarters · filed 2012-02-29 | $107.20M derived: sum of 3 quarters · filed 2012-02-29 | $109.20M 10-K · filed 2012-02-29 |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $2.00M derived: sum of 2 quarters · filed 2011-11-04 | $4.00M 10-Q · filed 2011-11-04 | $32.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2011-06-30 | $2.00M 10-Q · filed 2011-08-08 | $4.00M 10-Q · filed 2011-08-08 | $32.00M derived: sum of 3 quarters · filed 2012-02-29 | $32.00M derived: sum of 4 quarters · filed 2012-02-29 |
| 2011-03-31 | $2.00M 10-Q · filed 2011-05-10 | $30.00M derived: sum of 2 quarters · filed 2012-02-29 | $30.00M derived: sum of 3 quarters · filed 2012-02-29 | $40.24M derived: sum of 4 quarters · filed 2012-02-29 |
| 2010-12-31 | $28.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-29 | $28.00M derived: sum of 2 quarters · filed 2012-02-29 | $38.24M derived: sum of 3 quarters · filed 2012-02-29 | $89.25M 10-K · filed 2012-02-29 |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $10.24M derived: sum of 2 quarters · filed 2011-11-04 | $61.24M 10-Q · filed 2011-11-04 | |
| 2010-06-30 | $10.24M 10-Q · filed 2011-08-08 | $61.24M 10-Q · filed 2011-08-08 | ||
| 2010-03-31 | $51.00M 10-Q · filed 2011-05-10 | |||
| 2009-12-31 | $59.35M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |